Regional Cancer Care Associates

Dr. Robert Alter, MD

Claim this profile

Hackensack University Medical Center

Studies Skin Cancer
Studies Bladder Cancer
15 reported clinical trials
45 drugs studied

Area of expertise

1Skin Cancer
Robert Alter, MD has run 9 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
2Bladder Cancer
Robert Alter, MD has run 6 trials for Bladder Cancer. Some of their research focus areas include:
Stage IV
Stage III
HBcAb negative

Affiliated Hospitals

Image of trial facility.
Hackensack University Medical Center
Image of trial facility.
John Theurer Cancer Center

Clinical Trials Robert Alter, MD is currently running

Image of trial facility.

Standard Therapy + Surgery/Radiation

for Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting2 awards Phase 330 criteria
Image of trial facility.

Cabozantinib +/− Atezolizumab

for Advanced Kidney Cancer

This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the tumor and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of tumor cells. Combination therapy with atezolizumab and cabozantinib may shrink the tumor and allow a longer survival time in patients with metastatic renal cell carcinoma.
Recruiting1 award Phase 230 criteria

More about Robert Alter, MD

Clinical Trial Related8 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Robert Alter, MD has experience with
  • Nivolumab
  • Ipilimumab
  • Atezolizumab
  • Prednisone
  • Cabozantinib
  • Radiation Therapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Robert Alter, MD specialize in?
Is Robert Alter, MD currently recruiting for clinical trials?
Are there any treatments that Robert Alter, MD has studied deeply?
What is the best way to schedule an appointment with Robert Alter, MD?
What is the office address of Robert Alter, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security